Recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10 for 18-65 years old healthy people:randomized, blinded, parallel-group phase III clinical trial
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Mycobacterium riyadhense (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors AnHui Longcom Biologic Pharmacy
- 05 Jan 2017 Status changed from recruiting to completed.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.
- 28 Apr 2016 New trial record